Skip to Main Content

Paper Details

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
JAMA Oncol
8
2023
DAPHNe, ERBB2, ERBB2 (formerly, ERBB2-Positive Breast Cancer, ERBB2-positive breast cancer, HER2, HER2)-positive breast cancer, HER2DX, HER2DX genomic assay, I, Patients, Pertuzumab, Trastuzumab, carboplatin, docetaxel, formalin, pCR, patients, pertuzumab, trastuzumab, tumor, tumors
Author NameAffiliation
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyDana-Farber Brigham Cancer Center
Sara M TolaneyHarvard Medical School
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
  • 1 - 6

Datasets

Release 1.2